Skip to content

Effect of local unani formulation in Tinea Corporis.

A Randomized open label clinical trial of Marham Quba in the management of Quba (Tinea Corporis)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/03/064862
Enrollment
30
Registered
2024-03-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B354- Tinea corporis

Interventions

Intervention1: Marham Quba: Dose-5 gm. Frequency-Twice a day. Route of Administration-Locally Apply. Duration -6 Weeks. Control Intervention1: NOT APPLICABLE: NOT APPLICABLE Control Intervention2: NI

Sponsors

Government Tibbi College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Circumscribed lesions having any of the following signs and symptoms on body and limbs: a. Presence of pruritus and burning b. Presence of scales c. Presence of central clearing d. Erythematous papules 2. Participants with positive mycology (KOH positive). 3. Participants of either sex in age group of 10-60 years

Exclusion criteria

Exclusion criteria: 1. Co-morbid conditions of the participants. 2. Pregnant or Lactating Women. 3. Significant Pulmonary/Cardiovascular/Hepato- renal Dysfunction. 4. Known cases of Immuno-compromised states (HIV/ AIDS, etc.)/ Malignancies. 5. Participants not willing to attend treatment schedule regularly.

Design outcomes

Primary

MeasureTime frame
Total Signs and Symptoms Score (TSSS) Timepoint: at baseline, at 2 weeks, at 4 weeks and at 6 weeks.

Secondary

MeasureTime frame
Investigator’s Global Assessment (IGA)Timepoint: at 5th weeks.

Countries

India

Contacts

Public ContactDr Md Najibur Rahman

Government Tibbi College and Hospital

amudrshahnawaz@gmail.com9411209323

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026